In 2022, three gene therapies for rare conditions won approval in the United States. As these and other advanced therapies make it to market, drug companies and payers need to wrestle with pricing issues, particularly for one-and-done therapies that are potentially curative. We spoke to Alice Valder Curran, partner with Hogan Lovells, about the challenges of value-based pricing for gene therapies, some of the pricing approaches gene therapy developers are employing, and how the existing policy landscape complicates matters.